Roivant Sciences
ROIV
225 hedge funds and large institutions have $6.08B invested in Roivant Sciences in 2023 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 85 increasing their positions, 53 reducing their positions, and 41 closing their positions.
71% more call options, than puts
Call options by funds: $50.8M | Put options by funds: $29.7M
60% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 53
50% more funds holding in top 10
Funds holding in top 10: 14 → 21 (+7)
49% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 41
9% more funds holding
Funds holding: 206 → 225 (+19)
5% less capital invested
Capital invested by funds: $6.38B → $6.08B (-$294M)
1.6% less ownership
Funds ownership: 68.98% → 67.38% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$82.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$33.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$33.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$32.7M |
| 5 |
BlackRock
New York
|
+$30M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$124M |
| 2 |
PA
Perceptive Advisors
New York
|
-$44.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$41.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$39.6M |
| 5 |
Janus Henderson Group
London,
|
-$37.5M |
ROIV Hedge Fund Activity: Q4 2023 in Review
225 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q4 2023, worth a combined $6.08B — down 4.6% from $6.38B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new ROIV positions and 41 closed out — a net gain of 20 holders — while 85 added to existing stakes and 53 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $82.8M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $124M sold.
- 225 institutional investors held Roivant Sciences (ROIV) as of Q4 2023, up from 206 in Q3 2023.
- Funds reported $6.08B of Roivant Sciences stock for Q4 2023, down 4.6% quarter-over-quarter.
- 61 funds opened new Roivant Sciences positions in Q4 2023 and 41 closed out, a net change of +20 holders.
- The largest Roivant Sciences buyer in Q4 2023 was Rubric Capital Management (New York), an estimated $82.8M added.
- The largest Roivant Sciences seller in Q4 2023 was T. Rowe Price Investment Management, an estimated $124M sold.
Based on aggregated 13F filings for Q4 2023.